her2阳性乳腺癌伴中枢神经系统转移患者的精炼治疗

Pub Date : 2022-12-01 Epub Date: 2022-08-10 DOI:10.1159/000526431

Marta Filipa Freire Vaz Batista, Inês Eiriz, Amanda Fitzpatrick, Fanny Le Du, Sofia Braga, Diogo Alpuim Costa

{"title":"her2阳性乳腺癌伴中枢神经系统转移患者的精炼治疗","authors":"Marta Filipa Freire Vaz Batista, Inês Eiriz, Amanda Fitzpatrick, Fanny Le Du, Sofia Braga, Diogo Alpuim Costa","doi":"10.1159/000526431","DOIUrl":null,"url":null,"abstract":"Background: Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically omitted from clinical trials, recent studies of novel HER2-targeted agents have focused on HER2+ BM patients, addressing stable but also progressing BM and leptomeningeal carcinomatosis (LMC).Summary: This review aimed to summarize the most relevant data on treating patients with HER2+ BM and LMC.Key messages: The treatment paradigm for patients with HER2+ MBC has changed. Local therapies play an important role, but accumulating evidence on the intracranial activity and clinical benefit of anti-HER2 targeting therapies might lead to a shift in the paradigm on treating BM in the next few years towards more widespread use of systemic therapy.","PeriodicalId":72460,"journal":{"name":"","volume":"17 6","pages":"524-532"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801402/pdf/","citationCount":"0","resultStr":"{\"title\":\"Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis.\",\"authors\":\"Marta Filipa Freire Vaz Batista, Inês Eiriz, Amanda Fitzpatrick, Fanny Le Du, Sofia Braga, Diogo Alpuim Costa\",\"doi\":\"10.1159/000526431\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically omitted from clinical trials, recent studies of novel HER2-targeted agents have focused on HER2+ BM patients, addressing stable but also progressing BM and leptomeningeal carcinomatosis (LMC).Summary: This review aimed to summarize the most relevant data on treating patients with HER2+ BM and LMC.Key messages: The treatment paradigm for patients with HER2+ MBC has changed. Local therapies play an important role, but accumulating evidence on the intracranial activity and clinical benefit of anti-HER2 targeting therapies might lead to a shift in the paradigm on treating BM in the next few years towards more widespread use of systemic therapy.\",\"PeriodicalId\":72460,\"journal\":{\"name\":\"\",\"volume\":\"17 6\",\"pages\":\"524-532\"},\"PeriodicalIF\":0.0,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801402/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000526431\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/8/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000526431","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/10 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

背景:脑转移(BM)是转移性乳腺癌(MBC)的主要临床问题，50%的人表皮生长因子受体2阳性(HER2+)乳腺癌患者发生脑转移。在以往的临床试验中被忽略，最近对新型HER2靶向药物的研究主要集中在HER2+ BM患者身上，针对稳定但也进展中的BM和脑膜轻脑膜癌(LMC)。摘要:本综述旨在总结治疗HER2+ BM和LMC患者的最相关数据。HER2+ MBC患者的治疗模式已经改变。局部治疗发挥着重要的作用，但越来越多的证据表明，抗her2靶向治疗的颅内活性和临床益处可能会导致在未来几年内治疗脑转移的范式转向更广泛地使用全身治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis.

Background: Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically omitted from clinical trials, recent studies of novel HER2-targeted agents have focused on HER2+ BM patients, addressing stable but also progressing BM and leptomeningeal carcinomatosis (LMC).

Summary: This review aimed to summarize the most relevant data on treating patients with HER2+ BM and LMC.

Key messages: The treatment paradigm for patients with HER2+ MBC has changed. Local therapies play an important role, but accumulating evidence on the intracranial activity and clinical benefit of anti-HER2 targeting therapies might lead to a shift in the paradigm on treating BM in the next few years towards more widespread use of systemic therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助